There's no need to abandon abacavir as an option for AIDS treatment fearing adverse effects. This podcast features a new guideline that shows how to use easily ordered genetic tests to judge who can take the drug safely.
(AUDIO) Although abacavir is save and effective against HIV infection for many patients, some primary care doctors may be reluctant to use it, fearing adverse effects, says pharmacogenomic specialist Michael Martin, PharmD of the University of California's Department of Bioengineering and Therapeutic Sciences. A new guideline from the Clinical Pharmacogenomics Implementation Consortium tells exactly how to order the genetic tests that can determine whether or not the drug is safe, and how to act on them. In this brief interview, hear the lead author of the new guideline describe how you can use it to guide therapy.
Gene Tests Can Make Abacavir Safe for AIDS Treatment
For your reference:
Guidelines for HLA-B Genotype and Abacavir Dosing
Clinical Pharmacogenomics Implementation Consortium
Clinical Pharmacology and Therapeutics, February 29, 2012
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.